You are here: Industry Insights > GBT

News List

Voxelotor for haemolytic anaemia treatment gains positive opinion pharmatimes
January 27, 2022
MHRA awards a positive scientific opinion for voxelotor–a once-daily tablet for the treatment of haemolytic anaemia.
U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease Drugs
December 20, 2021
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of a supplemental New Drug Application (sNDA) for Oxbryta...
EMA begins review of GBT's sickle cell treatment Oxbryta pharmatimes
January 29, 2021
The European Medicines Agency (EMA) has accepted a marketing authorisation application for Global Blood Therapeutic’s (GBT) Oxbryta (voxelotor).
GBT and Syros team up on new therapies for blood disorders pharmaceutical-technology
December 23, 2019
Global Blood Therapeutics (GBT) has signed an agreement with Syros Pharmaceuticals for the discovery, development and commercialisation of therapies to treat two blood disorders.
GBT heads to FDA with sickle cell drug voxelotor pharmaphorum
December 05, 2018
Global Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of sickle cell disease drug voxelotor as part of a filing for accelerated approval.....
FDA agrees accelerated approval pathway for GBT’s voxelotor pharmaceutical-technology
December 05, 2018
The US Food and Drug Administration (FDA) has granted San Francisco-based Global Blood Therapeutics (GBT)’s sickle cell disease (SCD) therapy voxelotor an accelerated approval under the subpart H pathway.
GBT picks up Roche’s dropped heart drug for its sickle cell disease pipeline in $127M deal fiercebiotech
August 24, 2018
A discontinued heart disease drug may find new life as a treatment for sickle cell disease, with Roche handing off development of its antibody inclacumab to Global Blood Therapeutics.